Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.

Publication Type:

Journal Article


BJU international, Volume 107, Issue 10, p.1562-9 (2011)


2011, Biopsy, Epidemiologic Methods, Humans, Male, Middle Aged, Neoplasm Staging, Nomograms, Prostate-Specific Antigen, PROSTATECTOMY, Prostatic Neoplasms, Public Health Sciences Division


• To develop a '2010 Partin Nomogram' with total prostate-specific antigen (tPSA) as a continuous biomarker, in light of the fact that the current 2007 Partin Tables restrict the application of tPSA as a non-continuous biomarker by creating 'groups' for risk stratification with tPSA levels (ng/mL) of 0-2.5, 2.6-4.0, 4.1-6.0, 6.1-10.0 and >10.0. • To use a 'predictiveness curve' to calculate the percentile risk of a patient among the cohort.